Clinuvel Pharmaceuticals Limited (CUV.XA)
- Previous Close
15.20 - Open
15.26 - Bid 15.25 x --
- Ask --
- Day's Range
15.26 - 15.61 - 52 Week Range
12.98 - 21.43 - Volume
3,366 - Avg. Volume
13,261 - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
33.12 - EPS (TTM)
0.47 - Earnings Date Aug 26, 2024 - Aug 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.
www.clinuvel.com--
Full Time Employees
June 30
Fiscal Year Ends
--
Sector
--
Industry
Recent News: CUV.XA
Performance Overview: CUV.XA
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CUV.XA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CUV.XA
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
36.88%
Return on Assets (ttm)
14.71%
Return on Equity (ttm)
18.98%
Revenue (ttm)
81.76M
Net Income Avi to Common (ttm)
30.15M
Diluted EPS (ttm)
0.47
Balance Sheet and Cash Flow
Total Cash (mrq)
174.45M
Total Debt/Equity (mrq)
0.60%
Levered Free Cash Flow (ttm)
31.29M